BIOAEarnings•globenewswire•
BioAge Labs Reports Second Quarter 2025 Financial Results and Provides Business Updates
Sentiment:Negative (30)
Summary
Oral NLRP3 inhibitor BGE-102 on track for Phase 1 initiation in 2H 2025 with initial data by year-end
Original Article
Read the full article from the original source for complete details and context.
Read Full ArticleArticle published on August 6, 2025 by globenewswire